On the other hand, early investigations on the effect of PCSK9-R46L showed that carriers of this variant displayed a two-fold increase in the prevalence of hepatic steatosis [85], while more recent data suggest that the PCSK9-R46L variant is protective against liver damage in patients with NAFLD [80]. Here, PCSK9 is linked to metabolic dysfunction-associated steatotic liver disease.